Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease ...
Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen's in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a ...
Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab's AI platform, built on Latent-X2, to access ...
Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific, they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results